Given the previous findings, we hypothesized that by suppressing HER3 activity, KTN3379 would be able to suppress residual signaling through PI3K and would thus demonstrate synergistic anti-cancer activity when combined with BYL719. This evidence concerns the gene ERBB3 and cancer.